Eagle Pharmaceuticals, Inc. (EGRX)

Eagle Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Net Income	11.95	35.64	-8.63	11.99	14.31	31.9
Depreciation & Amortization	21.92	13.27	4.81	4.77	4.65	3.67
Share-Based Compensation	16.49	16.45	19.56	24.76	22	19.08
Other Operating Activities	-59.67	-14.66	12.49	7.99	15.02	-2.27
Operating Cash Flow	-9.32	50.7	28.22	49.5	55.99	52.38
Operating Cash Flow Growth	-	79.67%	-42.99%	-11.59%	6.88%	-11.09%
Capital Expenditures	-0.07	-0.18	-0.32	-0.75	-0.78	-0.13
Acquisitions	1.26	-74.15	0	0	0	0
Change in Investments	-25	-12.5	-5	-17.5	0	0
Investing Cash Flow	-23.81	-86.83	-5.32	-18.25	-0.78	-0.13
Share Issuance / Repurchase	-9.7	-16.26	-18.82	-31.35	-17.7	-64.49
Debt Issued / Paid	22.9	11.4	-8	-5	-6.33	-3.75
Other Financing Activities	-1.28	-1.36	-1.58	-1.53	-0.2	-19.88
Financing Cash Flow	11.92	-6.21	-28.39	-37.87	-24.23	-88.12
Net Cash Flow	-21.21	-42.34	-5.5	-6.62	30.98	-35.87
Free Cash Flow	-9.39	50.52	27.9	48.75	55.21	52.25
Free Cash Flow Growth	-	81.11%	-42.78%	-11.70%	5.66%	-4.10%
Free Cash Flow Margin	-3.65%	15.96%	16.26%	25.96%	28.18%	24.50%
Free Cash Flow Per Share	-0.72	3.91	2.14	3.62	4.01	3.54

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).